Clinical studies indicate that mGluR2 expression is lacking in high‐grade malignant GBM, such as ependymoma or medulloblastoma, whereas higher mGluR2 levels are observed in low‐grade astrocytomas [476]. Here, GRM2 is linked to medulloblastoma.